Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Modified Frailty Index (mFI) in Elderly Patients with Glioblastoma Correlates with Survival
P12 - Poster Session 12 (5:30 PM-6:30 PM)
Glioblastoma carriers a poor prognosis in elderly.  The mFI predicts post-surgical in-hospital mortality and shorter overall survival (OS).  We applied mFI-11 to a cohort of surgically confirmed glioblastoma within our institution to examine treatment and survival patterns. 
To compare overall survival in the most-frail elderly patients with the least-frail elderly patients with glioblastoma and establish if frailty score can be a useful predictor for patient prognosis and treatment success. 
We performed a retrospective cohort study from 2016-2021 in patients ³65 with glioblastoma. We applied a frailty score to each patient using the (mFI-11). We used the mFI-11 index to compare survival outcomes and NCCN recommended treatments.
We identified 108 patients ³65 with an EMR code for glioblastoma and excluded 41.  Of the 67 patients included in the analysis, 23 had mFI=0, 21 mFI=1, 15 mFI=22, and 6 had mFI >2. There was no significant difference in age (p=0.43) or KPS (p=0.25) between mFI£2 vs. >2, nor in % biopsy (43% vs 33%, p=0.21).  Patients with mFI>2 had shorter OS (20.8 ±18.4 mo vs 8.5 ±5.8 mo, p=0.01), shorter PFS6 (56% vs 27%, p=0.03), and OS at 24 months (28% vs 0, p<0.001).  The more-frail patients were less likely to complete radiation treatment completion (p=0.06), more likely to have a lower radiation dose (p=0.07), and less likely to complete chemotherapy (p=0.33), though not statistically significance.  They had longer hospital stay (p=0.04) and trended toward more rehospitalizations (p=0.08). 

Frailty is an underused metric for risk assessment in geriatric patients with glioblastoma and may be a useful tool in addition to age and performance status to help guide shared decision making in this population.

Amy K. Chang
Miss Chang has nothing to disclose.
Alissa A. Thomas, MD, FAAN (University of Vermont Medical Center) Dr. Thomas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roon. The institution of Dr. Thomas has received research support from Novocure. The institution of Dr. Thomas has received research support from Ono Pharmaceuticals.